[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Qiagen N.V. (QGEN)

Qiagen N.V. (QGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,525,322
  • Shares Outstanding, K 206,075
  • Annual Sales, $ 2,090 M
  • Annual Income, $ 424,880 K
  • EBIT $ 435 M
  • EBITDA $ 632 M
  • 60-Month Beta 0.64
  • Price/Sales 4.09
  • Price/Cash Flow 12.17
  • Price/Book 2.56

Options Overview Details

View History
  • Implied Volatility 50.91% (-2.69%)
  • Historical Volatility 36.70%
  • IV Percentile 78%
  • IV Rank 67.27%
  • IV High 65.79% on 03/13/26
  • IV Low 20.32% on 08/21/25
  • Expected Move (DTE 26) 2.64 (6.37%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 378
  • Volume Avg (30-Day) 1,366
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 32,920
  • Open Int (30-Day) 28,510
  • Expected Range 38.74 to 44.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.60
  • Number of Estimates 6
  • High Estimate $0.61
  • Low Estimate $0.60
  • Prior Year $0.63
  • Growth Rate Est. (year over year) -4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.69 +9.76%
on 07/08/26
44.03 -6.04%
on 07/09/26
+2.64 (+6.82%)
since 06/24/26
3-Month
32.53 +27.17%
on 05/13/26
44.03 -6.04%
on 07/09/26
+2.96 (+7.71%)
since 04/24/26
52-Week
32.53 +27.17%
on 05/13/26
57.81 -28.44%
on 01/20/26
-12.56 (-23.28%)
since 07/24/25

Most Recent Stories

More News
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide ...

QGEN : 41.37 (-0.19%)
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. Press release date / time: Wednesday, August 5 ...

QGEN : 41.37 (-0.19%)
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures ...

QGEN : 41.37 (-0.19%)
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas ...

QGEN : 41.37 (-0.19%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).  Such investors are advised to contact...

QGEN : 41.37 (-0.19%)
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak ...

QGEN : 41.37 (-0.19%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

NEW YORK , May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).  Such investors are advised to contact...

QGEN : 41.37 (-0.19%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN). Such investors are advised to contact...

QGEN : 41.37 (-0.19%)
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface ...

QGEN : 41.37 (-0.19%)
Qiagen (QGEN) Securities Fraud Investigation - Levi & Korsinsky

Qiagen shares dropped more than 10% after the company slashed FY 2026 sales-growth guidance from "at least 5% CER" to just 1-2% CER -- erasing hundreds of millions in market capitalization in a single...

QGEN : 41.37 (-0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed...

See More

Key Turning Points

3rd Resistance Point 42.11
2nd Resistance Point 41.87
1st Resistance Point 41.62
Last Price 41.37
1st Support Level 41.14
2nd Support Level 40.90
3rd Support Level 40.65

See More

52-Week High 57.81
Fibonacci 61.8% 48.16
Fibonacci 50% 45.17
Fibonacci 38.2% 42.19
Last Price 41.37
52-Week Low 32.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.